Y-mAbs Therapeutics
YMAB
YMAB was delisted on the 15th of September, 2025.
42 hedge funds and large institutions have $176M invested in Y-mAbs Therapeutics in 2018 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 10 increasing their positions, 10 reducing their positions, and 12 closing their positions.
42% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 12
14% more funds holding
Funds holding: 37 → 42 (+5)
2.98% more ownership
Funds ownership: 22.42% → 25.41% (+3%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 10
14% less capital invested
Capital invested by funds: $205M → $176M (-$29.7M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$9.09M |
| 2 |
BlackRock
New York
|
+$7.51M |
| 3 |
AllianceBernstein
Nashville,
Tennessee
|
+$5.31M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.95M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$1.79M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$3.32M |
| 2 |
AG
Artal Group
Luxembourg
|
-$2.3M |
| 3 |
Goldman Sachs
New York
|
-$1.69M |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
-$1.33M |
| 5 |
BBA
Baker Bros. Advisors
New York
|
-$1.08M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Point72 Asset Management
Stamford,
Connecticut
| – | -$133K | -5,000 | Closed |
|
|
PHK
52
Point72 Hong Kong
Hong Kong
| – | -$86K | -3,252 | Closed |
|
|
RCM
53
Riverhead Capital Management
Wilmington,
Delaware
| – | -$63K | -2,380 | Closed |
|
|
CSS
54
Cubist Systematic Strategies
Stamford,
Connecticut
| – | -$55K | -2,082 | Closed |
|
YMAB Hedge Fund Activity: Q4 2018 in Review
42 of the 4,489 institutional investors tracked by Wall St. Rank reported a position in Y-mAbs Therapeutics (YMAB) for Q4 2018, worth a combined $176M — down 14% from $205M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new YMAB positions and 12 closed out — a net gain of 5 holders — while 10 added to existing stakes and 10 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $9.09M. The largest seller was Farallon Capital Management, exiting entirely with an estimated $3.32M sold.
- 42 institutional investors held Y-mAbs Therapeutics (YMAB) as of Q4 2018, up from 37 in Q3 2018.
- Funds reported $176M of Y-mAbs Therapeutics stock for Q4 2018, down 14% quarter-over-quarter.
- 17 funds opened new Y-mAbs Therapeutics positions in Q4 2018 and 12 closed out, a net change of +5 holders.
- The largest Y-mAbs Therapeutics buyer in Q4 2018 was Fidelity Investments, an estimated $9.09M added.
- The largest Y-mAbs Therapeutics seller in Q4 2018 was Farallon Capital Management, an estimated $3.32M sold.
Based on aggregated 13F filings for Q4 2018.